Published in Clin Cancer Res on January 01, 2005
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol (2009) 2.33
Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells. Neoplasia (2009) 1.06
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl Med Biol (2011) 0.99
Efficacy of intracerebral delivery of cisplatin in combination with photon irradiation for treatment of brain tumors. J Neurooncol (2009) 0.99
The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia (2015) 0.96
Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem (2007) 0.92
Dendrimers in medical nanotechnology. IEEE Eng Med Biol Mag (2009) 0.86
Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget (2015) 0.86
Construction of a novel constitutively active chimeric EGFR to identify new targets for therapy. Neoplasia (2005) 0.86
Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors. J Neurooncol (2009) 0.85
Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model. J Mater Sci Mater Med (2010) 0.83
Targeted brain tumor treatment-current perspectives. Drug Target Insights (2007) 0.83
A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors. Cancer Biol Ther (2013) 0.82
Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model. PLoS One (2012) 0.79
Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors. Onco Targets Ther (2016) 0.77
EGFR Amplification and Glioblastoma Stem-Like Cells. Stem Cells Int (2015) 0.76
Radiolabeled the novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts. Oncotarget (2016) 0.75
In vivo effect of an luteinizing hormone-releasing hormone analog on vascular endothelial growth factor and epidermal growth factor receptor expression in mammary tumors. J Carcinog (2009) 0.75
Passive immunotherapeutic strategies for the treatment of malignant gliomas. Neurosurg Clin N Am (2012) 0.75
Glioma: experimental models and reality. Acta Neuropathol (2017) 0.75
Tumoricidal activity of low-energy 160-KV versus 6-MV X-rays against platinum-sensitized F98 glioma cells. J Radiat Res (2014) 0.75
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging (2002) 2.58
Towards hyperpolarized (13)C-succinate imaging of brain cancer. J Magn Reson (2007) 2.57
Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res (2006) 2.46
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol (2007) 2.39
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
PASADENA hyperpolarization of succinic acid for MRI and NMR spectroscopy. J Am Chem Soc (2008) 2.27
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy. World Neurosurg (2011) 2.05
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66
Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev (2006) 1.66
A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information. Mol Imaging (2006) 1.63
Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging (2012) 1.57
PASADENA hyperpolarization of 13C biomolecules: equipment design and installation. MAGMA (2008) 1.56
Hyperpolarized water as an MR imaging contrast agent: feasibility of in vivo imaging in a rat model. Radiology (2012) 1.54
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Developmental field defects: coming together of associations and sequences during blastogenesis. Am J Med Genet (2002) 1.50
Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging (2011) 1.50
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res (2004) 1.42
Quality assurance of PASADENA hyperpolarization for 13C biomolecules. MAGMA (2008) 1.41
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res (2006) 1.41
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res (2011) 1.39
Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys (2008) 1.39
Diffusion imaging for therapy response assessment of brain tumor. Neuroimaging Clin N Am (2009) 1.38
Iron-sulfur cluster biosynthesis. Kinetic analysis of [2Fe-2S] cluster transfer from holo ISU to apo Fd: role of redox chemistry and a conserved aspartate. Biochemistry (2002) 1.37
Real-time molecular imaging of tricarboxylic acid cycle metabolism in vivo by hyperpolarized 1-(13)C diethyl succinate. J Am Chem Soc (2011) 1.36
Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res (2006) 1.34
Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther (2006) 1.33
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res (2004) 1.33
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res (2007) 1.31
Parahydrogen-induced polarization (PHIP) hyperpolarized MR receptor imaging in vivo: a pilot study of 13C imaging of atheroma in mice. NMR Biomed (2011) 1.27
Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study. MAGMA (2003) 1.26
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res (2007) 1.26
A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia (2008) 1.25
Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res (2006) 1.25
A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging (2003) 1.25
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther (2004) 1.25
Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol (2004) 1.23
Dynamic imaging of emerging resistance during cancer therapy. Cancer Res (2006) 1.23
Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx (2005) 1.23
Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res (2008) 1.21
Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem (2009) 1.20
Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res (2007) 1.16
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther (2005) 1.16
The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res (2006) 1.15
Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am (2006) 1.15
Iron-sulfur cluster biosynthesis. Thermatoga maritima IscU is a structured iron-sulfur cluster assembly protein. J Biol Chem (2002) 1.15
Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging (2009) 1.15
Central nervous system cancers. J Natl Compr Canc Netw (2011) 1.13
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res (2010) 1.10
Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging (2003) 1.10
Stereotactic gamma knife surgery for trigeminal neuralgia: detailed analysis of treatment response. J Neurosurg (2005) 1.09
Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol (2008) 1.09
Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res (2006) 1.08
Enhanced survival and cure of F98 glioma-bearing rats following intracerebral delivery of carboplatin in combination with photon irradiation. Clin Cancer Res (2007) 1.07
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res (2013) 1.07
Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res (2008) 1.06